Taking license with natural killer cell maturation and repertoire development.
about
NK cells in therapy of cancerGenetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression.Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cellsNK cell terminal differentiation: correlated stepwise decrease of NKG2A and acquisition of KIRsNatural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).Complete characterization of killer Ig-like receptor (KIR) haplotypes in Mauritian cynomolgus macaques: novel insights into nonhuman primate KIR gene content and organization.KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motifInnate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.Opportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseProbabilistic bidirectional promoter switches: noncoding RNA takes control.Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immatureEngineering antigen-specific primary human NK cells against HER-2 positive carcinomasThe transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element.Effect of donor KIR2DL1 allelic polymorphism on the outcome of pediatric allogeneic hematopoietic stem-cell transplantationSignificant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245.Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responsesThe role of natural killer cells in hematopoietic stem cell transplantation.Immunosenescence of human natural killer cells.Use of allogeneic NK cells for cancer immunotherapy.The multiple faces of the decidual natural killer cell.The ap-2 clathrin adaptor mediates endocytosis of an inhibitory killer cell Ig-like receptor in human NK cells.Selective expansion of human natural killer cells leads to enhanced alloreactivityMolecular determinant-based typing of KIR alleles and KIR ligands.Activated notch supports development of cytokine producing NK cells which are hyporesponsive and fail to acquire NK cell effector functions.The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy.Expansion of CD56-negative, CD16-positive, KIR-expressing natural killer cells after T cell-depleted haploidentical hematopoietic stem cell transplantation.Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer.
P2860
Q28242241-FFB33675-7492-43E2-BC39-80CA6D0FF688Q33384422-C18B6E18-1986-4EA2-866E-258C06BB4711Q33445569-32EF93B5-EAF7-434F-B383-2E9C58EE2D27Q33654187-1CFC7198-32DD-410B-99E8-CBD6C35A3EABQ33672480-2484FCA1-67ED-4B68-9C53-82AC64E111A8Q33704001-E28F36BD-02DD-4375-B023-7C89B9E20D2CQ33851496-6C9F8F60-A737-4AC4-BCEB-A25E649DA006Q34056087-964B338C-28E7-423B-B47E-A30A7BB2408CQ34307792-F83083E3-8A8E-48BD-A6B0-99ABCAB43428Q34464408-78EB3FFC-D496-4CFC-B24F-C9BEE7135CCFQ34618454-B39F4599-3E35-49B3-9BE6-454B99E0D714Q35900982-282AAFEC-2C76-4F10-A279-B2C5269BA80CQ36970863-F0423553-24DE-468B-85B3-21D8A9B511A8Q37151177-ADFDBC25-2B67-4264-B59E-6F50AFCE5834Q37227672-99C2D46F-21E5-45EE-9679-064803C24F76Q37472014-FD6860D5-F5CB-4DF7-9276-17D1F7DE7F36Q37524719-C4B72DD3-1664-41E0-9435-8FE5F485D8E3Q37853569-59DE1549-E32B-486D-AB95-241219C00787Q37876092-2336D8D8-05B2-41C4-8946-E794C9CCA464Q37957140-B5FAFC97-FB89-4CAE-B18A-6845A1DE8ADAQ38085351-641D613E-F001-4459-9158-0536A00DA353Q38954981-885FCE03-3B6D-4EDB-907B-EEE3653A38CDQ39029073-7464DC59-BD27-443D-B834-042CFEFA08A0Q39607355-E6765DFB-1397-4A0E-8B40-0C9E46429405Q39891171-A48E7FA0-AE6F-4A18-BEAD-C2121F01CFF7Q47112002-AB312124-88EE-4F62-A71A-C3FF666EC4C6Q47156322-4B8E3FD1-24E5-420A-91B9-3F040D5D616DQ53260948-C948DF91-0953-4142-9967-6CA4700A9FF2Q54386534-A53855EC-EDCC-4814-B0AE-4B38A295851C
P2860
Taking license with natural killer cell maturation and repertoire development.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Taking license with natural killer cell maturation and repertoire development.
@ast
Taking license with natural killer cell maturation and repertoire development.
@en
type
label
Taking license with natural killer cell maturation and repertoire development.
@ast
Taking license with natural killer cell maturation and repertoire development.
@en
prefLabel
Taking license with natural killer cell maturation and repertoire development.
@ast
Taking license with natural killer cell maturation and repertoire development.
@en
P2860
P1476
Taking license with natural killer cell maturation and repertoire development.
@en
P2093
Peter Parham
P2860
P304
P356
10.1111/J.1600-065X.2006.00462.X
P577
2006-12-01T00:00:00Z